CYCART19
LIVE

Serial Number

90766689

Owner

CELULARITY, INC.

Attorney

Camille M. Miller

First Use Date

Jan 7, 2020

Filing Date

Jun 10, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CYCART19 Trademark

Serial Number: 90766689 • Registration: 7064864

CYCART19 is a trademark filed by CELULARITY, INC. on June 10, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

CELULARITY, INC. (50 trademarks)

33 TECHNOLOGY DRIVE
WARREN, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

June 10, 2021

Registration Date

May 30, 2023

First Use Anywhere

January 7, 2020

First Use in Commerce

June 2, 2021

Published for Opposition

March 14, 2023

Goods & Services

Cells and biological preparations intended for medical and clinical use, namely, blood, stem cells, placental-derived cells, umbilical cord cells, placental-derived T cells, chimeric antigen receptor (CAR) T cells, umbilical cord blood, and placental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; human amniotic membrane and human chorionic membrane intended for subsequent implantation; human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological products for medical use, namely, placental-derived natural killer cells, and placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen; biological tissue intended for use as a wound covering and burn dressing; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds and burns; and written instructional materials distributed in connection with the aforesaid goods; biological products for medical use, namely, placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen

bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research; placental-derived cells, chimeric antigen receptor (CAR) T cells, and placental-derived T cells with a chimeric antigen receptor (CAR), all for use in scientific, laboratory and medical research

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 30, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
May 30, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 14, 2023 NPUB
PUBLISHED FOR OPPOSITION
Mar 14, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 22, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 6, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 3, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 3, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 3, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 3, 2023 CNEA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 16, 2022 ERFR
EX PARTE APPEAL-INSTITUTED
Dec 16, 2022 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Dec 16, 2022 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Dec 16, 2022 EXAF
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 16, 2022 GNFN
FINAL REFUSAL E-MAILED
Jun 16, 2022 GNFR
FINAL REFUSAL WRITTEN
Jun 16, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 13, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 12, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 12, 2022 TROA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Mar 9, 2022 AAUA
USE AMENDMENT ACCEPTED
Mar 8, 2022 IUAA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 8, 2022 GNRN
NON-FINAL ACTION E-MAILED
Mar 8, 2022 GNRT
NON-FINAL ACTION WRITTEN
Mar 8, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 1, 2022 DOCK
AMENDMENT TO USE PROCESSING COMPLETE
Sep 2, 2021 AUPC
USE AMENDMENT FILED
Sep 2, 2021 IUAF
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 31, 2021 NWOS
TEAS AMENDMENT OF USE RECEIVED
Jun 15, 2021 EAAU
NEW APPLICATION ENTERED
Jun 14, 2021 NWAP